Hugo Fry – Managing Director, Sanofi UK
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
Address: Sanofi-Aventis, One Onslow Street, Guildford, Surrey GU1 4YS, United Kingdom
Tel: +44 (0)1483 505 515
Web: http://www.sanofi.co.uk/l/gb/en/index.jsp
Sanofi UK, an affiliate of the global pharmaceutical company Sanofi, is a dynamic, rapidly growing organisation that is working to meet the needs of healthcare professionals and their patients.
Sanofi in the UK provides medicines to treat patients with illnesses in several therapeutic areas: cardiovascular, thrombosis, central nervous system, oncology, metabolic disorders and internal medicine
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic…
What are the priorities on your agenda as the new head of ABPI considering the successes and difficulties the association has experienced in the past? If you look at the…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market conditions in the US. In this context, how has the company been…
Thank you for having us today! You have been chief executive of the Association since 1990 and obviously observed the evolution of the OTC market from close by. From your…
Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these…
See our Cookie Privacy Policy Here
